Pirtobrutinib in R/R MZL: insights from the BRUIN trial
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, discusses findings from the Phase I/II BRUIN trial (NCT03740529), investigating the efficacy of the reversible BTK inhibitor (BTKi) pirtobrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL). The trial showed promising preliminary efficacy of this drug, with a 50% overall response rate (ORR) and median progression-free survival (PFS) of 15.6 months in this patient population. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Смотрите видео Pirtobrutinib in R/R MZL: insights from the BRUIN trial онлайн без регистрации, длительностью часов минут секунд в хорошем качестве. Это видео добавил пользователь VJHemOnc – Video Journal of Hematology & HemOnc 29 Январь 2024, не забудьте поделиться им ссылкой с друзьями и знакомыми, на нашем сайте его посмотрели 85 раз и оно понравилось 2 людям.